William D Young
CIK 1217420 · Chairman and CEO · last filed 2026-07-01
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Charts
Trading activity, where the exposure sits, and each trade against the stock price.
VRTX price and trades
Daily close with each Form 4 filing on this company marked: green = open-market buy, red = open-market sale, purple = grants, exercises, gifts and other non-market transactions. Marker size scales with the dollar value.
Shares held
Shares owned after each reported transaction on this company (direct holdings as reported).
Open-market buying and selling
by monthDollar value of open-market purchases (code P, up) and sales (code S, down) across all companies, by filing month. Grants, exercises and gifts are excluded.
Exposure by company
latestMost recently reported shares × current price. Faded bars (*) have had no filing in 3 years, so the person may no longer hold them. Click a bar to chart that company.
Filer Profile
SOUTH SAN FRANCISCO, CA 94080
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| AUTL | Director | — | $1.32 | — | $0 | 1 | 2026-07-01 |
| PRAX | Director | 3,269 | $332.97 | $1.09M | $0 | 7 | 2026-06-12 |
| Theravance Biopharma, Inc. (TBPH) Delisted | Director | 78,010 | $17.03 | $1.33M | $0 | 8 | 2022-04-28 |
| VRTX | Director | 29,311 | $550.87 | $16.15M | -$10.94M | 8 | 2020-06-03 |
| BMRN | Director | 11,875 | $57.18 | $679.0K | $0 | 5 | 2015-06-18 |
| Innoviva, Inc. (THRX) Delisted | Director | 52,129 | $4.06 | $211.6K | -$388.0K | 10 | 2013-04-26 |
| Monogram Biosciences, Inc. (MGRM) Delisted | Chairman and CEO | 43,852 | $6.00 | $263.1K | $105.5K | 5 | 2009-01-22 |
Recent Filings · Page 2 of 5
44 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2020-06-03 | VRTX | Grant (A) | — | $0 | EDGAR |
| 2020-04-30 | Theravance Biopharma, Inc. (TBPH) Delisted | Grant (A) | +6,635 | $0 | EDGAR |
| 2020-01-06 | VRTX | Mixed | — | -$2.94M | EDGAR |
| 2020-01-02 | VRTX | Mixed | — | -$4.59M | EDGAR |
| 2019-06-04 | VRTX | Grant (A) | +2,381 | $0 | EDGAR |
| 2019-05-02 | Theravance Biopharma, Inc. (TBPH) Delisted | Grant (A) | +8,385 | $0 | EDGAR |
| 2018-06-05 | VRTX | Grant (A) | +1,801 | $0 | EDGAR |
| 2018-05-03 | Theravance Biopharma, Inc. (TBPH) Delisted | Grant (A) | +8,186 | $0 | EDGAR |
| 2017-06-05 | VRTX | Mixed | +2,188 | $0 | EDGAR |
| 2017-05-18 | Theravance Biopharma, Inc. (TBPH) Delisted | Grant (A) | +6,000 | $0 | EDGAR |
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.